Warning: Trying to access array offset on value of type bool in /var/www/vhosts/oncodaily.com/public_html/pub/themes/oncodailynews/single.php on line 25
Warning: Trying to access array offset on value of type bool in /var/www/vhosts/oncodaily.com/public_html/pub/themes/oncodailynews/single.php on line 26
Feb 5, 2024, 11:27
Stephen V Liu: The optimal strategy for unresectable stage III NSCLC after chemoradiation in EGFR mutant NSCLC
Stephen V Liu, Director of Thoracic Oncology and Developmental Therapeutics at Lombardi Comprehensive Cancer Center, posted on X/Twitter:
“What is the optimal strategy for unresectable stage III NSCLC after chemoradiation in EGFR mutant NSCLC? Retrospective look JTO and JTO CRR (n=136) shows 2y rwPFS rate 86% with osimertinib, 30% with durvalumab, 27% with observation. Await prospective data from the phase III LAURA trial.
Point against immunotherapy: In 45 patients who progressed after consolidation durvalumab (PACIFIC), 37 then received EGFR TKI therapy. In those patients, 38% develped trAEs including 14% pneumonitis and 14% diarrhea.”
Read further.
Source: Stephen V Liu/X